Analyst firms · William Blair · NTLA
William Blair NTLA price target and rating history
Intellia Therapeutics Inc. (NTLA) · Health Care
William Blair rates Intellia Therapeutics Inc. (NTLA) Outperform with a $144 price target, as of its latest action on Mar 2, 2026. It has published 4 rating actions on NTLA since February 2022, including 1 upgrade and 1 downgrade.
- Current rating
- Outperform
- Price target
- $144
- Median target, all firms
- Too few
- Actions on NTLA
- 4
Every William Blair rating on NTLA
- Mar 2, 2026
- Oct 27, 2025
- Feb 18, 2022
- Feb 18, 2022
How other firms rate NTLA
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Barclays | Underweight | $8 | Oct 6, 2026 |
| Wolfe Research | Underperform | $9 | Jul 16, 2026 |
| William Blair | Outperform | Mar 2, 2026 |
Questions about William Blair and NTLA
- What is William Blair's price target for NTLA?
- William Blair's latest stated price target for Intellia Therapeutics Inc. (NTLA) is $144, from its action on Feb 18, 2022.
- What is William Blair's rating on NTLA?
- William Blair rates NTLA Outperform, a bullish rating, as of Mar 2, 2026.
- When did William Blair last change its view on NTLA?
- On Mar 2, 2026, William Blair upgrades to Outperform from Mkt Perform.
More NTLA rating histories
All William Blair ratingsNTLA news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.